BFLY

BUTTERFLY NETWORK INC

Healthcare | Mid Cap

-$0.05

EPS Forecast

$29.45

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Butterfly Network’s Q3 2026: A New Wing for Embedded Revenue and Federal Ambitions

Ticker: BFLY • Quarter ended September 30, 2026 • Revenue: $32.6 million • Gross margin: 73% • Source: Butterfly Network, Inc. EX-99.1 press release

Lead: A quarter that leans into growth, not nostalgia for monaural ultrasound

Butterfly Network, Inc. (NYSE: BFLY) reported its third quarter 2026 results with a narrative that reads more like a strategy memo than a one-off earnings flutter. Revenue came in at $32.6 million, underscoring a mix of Embedded revenue and traditional device sales, while the company boasted its highest gross margin in company history at 73%. The headline is not just the number, but the tone: management raised the full-year revenue and adjusted EBITDA guidance, and the press release frames the quarter as a confirmation that the firm’s Ultrasound-on-Chip platform is moving from pipeline to paychecks, even as the product roadmap presses forward with next-gen chips and broader platform ambitions. In earnings-speak, these are the kind of details that analysts tuck into EPS consensus rather than duet with revenue forecasts; Butterfly’s focus remains on non-GAAP metrics like adjusted EBITDA, though the market will still care about the traditional EPS line where it exists.

For readers scanning for the familiar, the document doesn’t pretend to deliver a clean EPS figure in this excerpt. Instead, it highlights revenue trajectory, gross-margin expansion, and a widening pipeline across embedded software partners, federal channels, and care-delivery solutions. It’s a reminder that in complex hardware-software plays, the “earnings surprise” is often about the trajectory of non-GAAP measures and embedded revenue mix, not a single quarterly print of per-share results. And yes, the ticker remains BFLY, a company bending the arc of ultrasound into cloud-enabled AI and federal readiness.

Operational and strategic highlights that catch the eye

  • Embedded revenue momentum: Butterfly emphasizes growth from its Embedded ecosystem, noting three BCI partners and the market launch of a partner product built on Butterfly technology in October 2026. This is the kind of news that could feed an earnings surprise narrative if embedded deals scale quickly into revenue.
  • Compass AI and Enterprise Momentum: The company closed five seven-figure and ten six-figure TCV enterprise deals in the quarter, signaling traction in larger commercial contracts beyond traditional device sales.
  • FedRAMP authorization: Official authorization expands federal and VA pipeline opportunities, a milestone that can anchor longer sales cycles but offer durable, multi-year revenue streams for a technology platform with cloud-native components.
  • Medical education and partnerships: The Lighthouse program with VCOM, designed to equip students with Butterfly devices and capture usage insights, points to a broader data-and-services strategy that could support recurring revenue layers.
  • International and care-delivery footprint: International expansion in Brazil and a new distribution partner in Taiwan, plus momentum in Home & Community Care, indicate geographic diversification that can moderate domestic cyclicality.
  • Innovation roadmap: Apollo chip development remains on schedule; a limited wearable research device release for Embedded partners and a next-generation product powered by the P5.1 chip anticipated in early 2027 keeps the growth narrative in motion.

Financials and guidance: a beat that leans into guidance

The quarter’s revenue beat came with a line about surpassing the high end of quarterly revenue and adjusted EBITDA guidance. That phrasing matters more in the current cycle than any single dollar figure, because it signals management’s confidence in the runway ahead—even as analysts weigh the relative weight of Embedded versus device revenue and the economics of federal contracts in a climate of careful government spending.

Butterfly’s gross margin of 73% marks a notable profitability milestone on a company that blends hardware, software, and services. In a market where many device makers face pressure on margins, this level of gross profitability supports a more durable economics narrative around Embedded platforms and cloud-enabled AI features.

On the earnings front, the release emphasizes adjusted EBITDA guidance rather than a traditional EPS figure. As a result, investors tracking earnings per share will look for either a future GAAP reconciliation or a clear path to an EPS proxy, while the EPS consensus for the year remains a function of how much of the Embedded revenue converts into recurring earnings versus one-off licensing or partnership revenue.

Outlook: what the quarter portends for Butterfly and peers

The raised full-year revenue and adjusted EBITDA guidance suggests Butterfly sees durable demand for its Ultrasound-on-Chip technology and an expanding cloud software layer that makes its hardware more valuable over time. The FedRAMP milestone could be a differentiator in the public-sector arena, potentially broadening opportunities beyond initial federal programs and into broader enterprise health and education markets that value secure, scalable cloud-enabled devices.

For sector peers, Butterfly’s narrative underscores a broader industry shift: hardware devices increasingly anchor long-term software and services streams, with embedded ecosystems driving stickiness. Companies combining device technologies with cloud services and AI-powered analytics may gain multi-year visibility, even as short-term revenue scales hinge on partner programs, regulatory clearances, and government contracts.

Investors will watch whether the embedded revenue acceleration sustains momentum into 2027 and how the P5.1-powered roadmap translates into margin expansion. If the company can maintain its 70%+ gross margin while growing embedded revenue, the balance sheet and the stock’s narrative could diverge from peers that struggle to monetize software layers atop hardware without eroding margins.

Risks and counterpoints: what could go sideways

Key questions revolve around sustainability of the embedded revenue cadence and the pace at which federal and enterprise deals convert to recurring revenue. A higher reliance on embedded licensing arrangements, or slower-than-expected adoption of new Embedded partner products, could pressure the revenue forecast and complicate a clean EPS trajectory. Regulatory shifts, supply-chain dynamics for chips, and competitive pressure in AI-enabled ultrasound may also compress margins or shift timelines for next-generation launches.

Bottom line: Butterfly spreads its wings while tightening the frame

Butterfly Network’s Q3 2026 results present a company increasingly defined by an ecosystem: embedded hardware, cloud software, and strategic partnerships that push revenue toward a recurring, multiyear cadence. The beat on guidance, a robust gross margin, and a raised revenue trajectory all align to a thesis where the stock’s appetite for growth could outpace the more skeptical currents in the sector—at least for now. For investors eyeing the space, the immediate takeaway is not a single number, but a set of architecture choices: how durable is the Embedded revenue line, how fast does FedRAMP-enabled expansion materialize, and can the next-gen Apollo/P5.1 roadmap deliver the margin expansion needed to turn long-run aspirations into near-term earnings reliability?

In short, BFLY is not merely fluttering. It’s building a canopy—one partnership, one chip, and one enterprise contract at a time.